Physician profile
Justin Barclay Roy
NPI 1528599008
$6,090.38
in general payments reported to CMS, 2019-2025
19 companies · $582 in 2025
The $582 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $730 · 2022: $1,567 · 2023: $1,661 · 2024: $1,550 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,614 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,614.16 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,722.23 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $813.54 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $572.84 | 2021-2025 | Gattex, Entyvio |
| Gilead Sciences, INC. | $361.43 | 2022-2024 | Epclusa, Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $349.99 | 2022-2024 | Zeposia |
| Medtronic, INC. | $340.85 | 2022-2023 | Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.19 | 2021-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $283.21 | 2021-2023 | Ocaliva |
| Laborie Medical Technologies Corp. | $268.57 | 2024 | Alphaone |
| Boston Scientific Corporation | $263.48 | 2022-2024 | |
| Celgene Corporation | $185.08 | 2022-2024 | Zeposia |
| Genzyme Corporation | $170.31 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Mirum Pharmaceuticals, INC. | $68.41 | 2023-2024 | Livmarli |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $44.03 | 2023-2025 | Ibsrela |
| Capsovision, INC. | $39.41 | 2023-2024 | Capsocam Plus |
| Pfizer INC. | $25.31 | 2024 | |
| Blueprint Medicines Corporation | $23.52 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.